ScreenerHero

KZIAKazia Therapeutics Limited

NAS · US · Healthcare · Biotechnology · kaziatherapeutics.com
13.40USDMkt Cap: 153.18M $P/E: —

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap153.18M $
Enterprise Value85.49M $
Revenue (TTM)1.90M $
Gross Profit1.90M $
Net Income (TTM)-20.70M $
Revenue/Share0.8510 USD
Last Price13.40 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-883.54
PEG1.01
EV/EBITDA-4.79
EV/Revenue45.03
P/S82.27
P/B4.73
EPS (TTM)-7.56
EPS (Forward)-0.02
52W Range
13.0638% of range13.96
52W High13.96 USD
52W Low13.06 USD
Profitability
Gross Margin100.00%
Oper. Margin-14641.04%
EBITDA Margin0.00%
Profit Margin-49290.48%
ROE249.39%
ROA-341.56%
Growth
Revenue Growth312.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-13.28M $
CapEx (TTM)—
FCF Margin57.93%
FCF Yield0.72%
Net Debt-69.36M $
Net Debt/EBITDA3.89
Balance Sheet
Debt/Equity-0.05
Current Ratio2.87
Quick Ratio2.86
Book Value/Sh2.892 USD
Cash/Share6.127 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 14, 2017
Splits
Last Split1:5
Split DateApr 17, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.36 USD
Upside (mean)+111.6%
Target Range17.85 USD – 34.57 USD
$17.85+111.6% to mean$34.57
# Analysts6
Ownership
Shares Out.11.43M
Float8.62M
Insiders19.81%
Institutions41.53%
Short Interest
Short Ratio3.5d
Short % Float5.95%
Short % Out.5.94%
Shares Short679.04K
Short (prev mo.)646.05K
Technical
SMA 5013.34 (+0.5%)
SMA 20010.16 (+32.0%)
Beta2.14
S&P 52W Chg21.00%
Avg Vol (30d)148.97K
Avg Vol (10d)192.01K
Technical Indicators
RSI (14)50.8
MACD0.1811
MACD Signal0.1034
MACD Hist.+0.0777
BB Upper14.59 USD
BB Middle13.09 USD
BB Lower11.58 USD
BB Width23.00%
ATR (14)1.055 USD
Vol Ratio (20d)0.73x